These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 17873698)
1. Comments on "neurological soft signs in schizophrenic patients treated with conventional and atypical antipsychotics". Varma A J Clin Psychopharmacol; 2007 Oct; 27(5):528. PubMed ID: 17873698 [No Abstract] [Full Text] [Related]
2. Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star? Chan RC; Gottesman II Neurosci Biobehav Rev; 2008 Jul; 32(5):957-71. PubMed ID: 18462797 [TBL] [Abstract][Full Text] [Related]
3. [Neurological soft signs in schizophrenic patients and their nonaffected siblings]. Mechri A; Slama H; Bourdel MC; Chebel S; Mandhouj O; Krebs MO; Gaha L Encephale; 2008 Oct; 34(5):483-9. PubMed ID: 19068337 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216 [TBL] [Abstract][Full Text] [Related]
8. [Neuroleptic treatment and neurological soft signs in schizophrenic patients]. Mechri A; Slama H; Chebel S; Mandhouj O; Gaha L Therapie; 2007; 62(5):449-53. PubMed ID: 18206107 [TBL] [Abstract][Full Text] [Related]
9. SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. Musil R; Spellmann I; Riedel M; Dehning S; Douhet A; Maino K; Zill P; Müller N; Möller HJ; Bondy B J Psychiatr Res; 2008 Oct; 42(12):963-70. PubMed ID: 18191416 [TBL] [Abstract][Full Text] [Related]
10. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective. Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748 [TBL] [Abstract][Full Text] [Related]
11. Performance of a neuro-fuzzy model in predicting weight changes of chronic schizophrenic patients exposed to antipsychotics. Lan TH; Loh EW; Wu MS; Hu TM; Chou P; Lan TY; Chiu HJ Mol Psychiatry; 2008 Dec; 13(12):1129-37. PubMed ID: 18180752 [TBL] [Abstract][Full Text] [Related]
12. Prolactin awareness: an essential consideration for physical health in schizophrenia. Montejo AL Eur Neuropsychopharmacol; 2008 May; 18 Suppl 2():S108-14. PubMed ID: 18346598 [TBL] [Abstract][Full Text] [Related]
13. Duration of untreated psychosis and it's effect on the symptomatic recovery in schizophrenia - preliminary results. Novak Sarotar B; Pesek MB; Agius M; Kocmur M Neuro Endocrinol Lett; 2008 Dec; 29(6):990-4. PubMed ID: 19112411 [TBL] [Abstract][Full Text] [Related]
14. Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms. Kwon JS; Joo YH; Nam HJ; Lim M; Cho EY; Jung MH; Choi JS; Kim B; Kang DH; Oh S; Park T; Hong KS Arch Gen Psychiatry; 2009 Nov; 66(11):1233-41. PubMed ID: 19884611 [TBL] [Abstract][Full Text] [Related]
15. Correlations of attitudes toward antipsychotic drugs with insight and objective psychopathology in schizophrenia. Rocca P; Crivelli B; Marino F; Mongini T; Portaleone F; Bogetto F Compr Psychiatry; 2008; 49(2):170-6. PubMed ID: 18243890 [TBL] [Abstract][Full Text] [Related]
16. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716 [TBL] [Abstract][Full Text] [Related]
17. No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with characteristics and treatment response to atypical antipsychotic agents in schizophrenic patients. Lee HY; Kim DJ; Lee HJ; Choi JE; Kim YK Prog Neuropsychopharmacol Biol Psychiatry; 2009 Mar; 33(2):276-80. PubMed ID: 19059448 [TBL] [Abstract][Full Text] [Related]
18. Neurocognitive effects of atypical and conventional antipsychotic drugs in schizophrenia: a naturalistic 6-month follow-up study. Wittorf A; Sickinger S; Wiedemann G; Klingberg S Arch Clin Neuropsychol; 2008 May; 23(3):271-82. PubMed ID: 18272323 [TBL] [Abstract][Full Text] [Related]
19. [Psychomotor symptoms in schizophrenia: the importance of a forgotten syndrome]. Morrens M; Hulstijn W; Sabbe BG Tijdschr Psychiatr; 2008; 50(11):713-24. PubMed ID: 18991232 [TBL] [Abstract][Full Text] [Related]
20. Spatial working memory and problem solving in schizophrenia: the effect of symptom stabilization with atypical antipsychotic medication. Snyder PJ; Jackson CE; Piskulic D; Olver J; Norman T; Maruff P Psychiatry Res; 2008 Sep; 160(3):316-26. PubMed ID: 18579217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]